In 2019, Wan group described the first Cdc20 degrader 165 (CP5V, Fig. 42).288 The degrader 165 (CP5V) induced the degradation of Cdc20 resulted in significant inhibition of breast cancer cell proliferation and resensitization of paclitaxel-resistant cell lines. This evidence concerns the gene CDC20 and breast carcinoma.